Table 1 Clinicopathological features of the patients at diagnosis.

From: Prognostic factors and outcomes of adjuvant and first-line metastatic treatments in melanoma a Turkish oncology group study

Age, year

Median (Interquartile range)

53 (18–85)

Gender, n (%)

Female

Male

39 (32.5)

81 (67.5)

ECOG-performance score, n (%)

0

1–2

76 (63.3)

44 (36.7)

Melanoma subtype, n (%)

Cutaneous

Acral

107 (89.2)

13 (10.8)

Lymph node metastasis types, n (%)

In-transit

Satellite

Microsatellite

Unknown

15 (12.5)

29 (24.2)

7 (5.8)

69 (57.5)

Stage, n (%)

IIIB

IIIC

IIID

33 (27.5)

71 (59.2)

16 (13.3)

Ulceration status, n (%)

Presence

Absence

NA

68 (56.7)

48 (40.0)

4 (3.3)

Localization, n (%)

Head and neck

Torso

Upper extremity

Lower extremity

35 (29.2)

27 (22.5)

20 (16.7)

38 (31.7)

BRAF mutation, n (%)

Mutant V600E

Mutant V600K

Other mutation

Wild type

Unknown

68 (56.7)

5 (4.2)

6 (5.0)

38 (31.7)

3 (2.5)

Adjuvant treatment option, n (%)

Nivolumab

Dabrafenib plus trametinib

Interferon

39 (32.5)

37 (30.8)

44 (36.7)

LDH

Above the UNL

Below the UNL

Unknown

23 (19.2)

68 (56.7)

29 (24.2)

  1. ECOG: Eastern Cooperative Oncology Group; LDH: Lactate dehydrogenase; UNL indicates upper normal limit.
Back to article page